Objective: Despite recent advancements in assisted reproductive technology (ART), the effective management of patients with poor ovarian response (POR) remains a formidable challenge. While various treatment strategies and predictors of live births have been documented to provide guidance to fertility specialists in managing poor responders, research efforts have predominantly encompassed all POSEIDON groups. In this study, our objective was to analyze the factors correlated with live births (LB) within a subset of the POSEIDON groups, with a particular focus on POSEIDON groups 3 and 4.
Patients And Methods: Charts of 406 patients belonging to POSEIDON groups 3 and 4 who underwent ART treatment at a university-affiliated infertility clinic following a gonadotropin-releasing hormone (GnRH) antagonist cycle between January 2016 and December 2021 were analyzed. Clinically significant factors associated with live births were incorporated into a logistic regression model for multivariate analysis to ascertain independent predictors of LB. Additionally, a receiver operating characteristic (ROC) curve analysis was conducted to establish the optimal cut-off values.
Results: Live births were achieved in 48 cycles (8.7%). Female age (OR, 0.930; 95% CI: 0.874-0.991; p < 0.024), baseline serum luteinizing hormone (LH) levels (OR, 0.854; 95% CI: 0.741-0.984; p < 0.029), and dual triggers (OR, 4.004; 95% CI: 1.290-12.426; p < 0.016) were identified as independent factors associated with LB following multivariate logistic regression analysis. The optimal age cut-off was determined to be 33 years, with a sensitivity of 70.8% and specificity of 75%.
Conclusions: Younger age, lower baseline serum LH levels, and dual-trigger administration appear to enhance the likelihood of live birth in POSEIDON groups 3 and 4 following treatments with the GnRH antagonist protocol.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.26355/eurrev_202402_35478 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Homozygous Variant in HSD17B1 Identified in Women With Poor Ovarian Response.
Clin Genet
January 2025
NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of Basic Medical Sciences, Central South University, ChangSha, China.
An increasing number of patients utilizing in vitro fertilization (IVF) and assisted reproductive technology (ART) are characterized as impaired or poor ovarian responders (PORs). Owing to its unclear molecular etiology, the management of patients with age-related ovarian characteristics remains a controversial and complex clinical concern. Therefore, it is important to identify and understand the etiological causes behind POR to develop more effective and efficient management strategies for these patients.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the safety and effectiveness of alfapump for controlling ascites and improving patients' quality of life.
- Results showed a significant reduction in the need for therapeutic paracentesis (TP) after implanting alfapump, with most patients experiencing over a 50% decrease in sessions.
- While some complications led to device removal, overall, the alfapump improved symptoms and physical health, suggesting it could be a viable option for patients with refractory ascites.
The Effect of Traditional Chinese Medicine Treatment on the Cumulative Live Birth Rate of Patients with Poor Ovarian Response to the Patient-Oriented Strategies Encompassing Individualized Oocyte Number Criteria.
Int J Womens Health
December 2024
Department of Traditional Chinese Medicine, Shenzhen Key Laboratory of Reproductive Immunology for Peri-Implantation, Shenzhen Zhongshan Institute for Reproductive Medicine and Genetics, Shenzhen Zhongshan Obstetrics & Gynecology Hospital (Formerly Shenzhen Zhongshan Urology Hospital), Shenzhen City, Guangdong Province, 518000, People's Republic of China.
Objective: This study analyzed the role of traditional Chinese medicine (TCM) treatment on the cumulative live birth rate (CLBR) in women with poor ovarian response to the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) criteria.
Methods: This cohort study selected 3347 patients with low ovarian response and divided them into four subgroups according to the POSEIDON criteria: Group 1 (n=947), Group 2 (n=778), Group 3 (n=164), and Group 4 (n=1458). Logistic regression analysis was used to evaluate the role of TCM treatment on the CLBR of patients with poor ovarian response to POSEIDON criteria.
Development and validation of a nomogram for failure to collect oocytes in POSEIDON Groups 3 and 4 undergoing IVF/ICSI treatment.
Sci Rep
December 2024
Center for Reproductive Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
This study aimed to develop and validate a predictive model for failure to collect oocytes in the Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) Groups 3 and 4 during their first in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) cycle. A retrospective analysis was conducted on patients in POSEIDON Groups 3 and 4 who underwent their first IVF/ICSI cycle at our center from January 2016 to December 2023. A total of 2,373 patients were randomly assigned to the training or validation cohort at a ratio of 6:4.
View Article and Find Full Text PDFFSH/LH co-stimulation in Advanced Maternal Age (AMA) and hypo-responder patients - Arabian gulf delphi consensus group.
Front Endocrinol (Lausanne)
December 2024
The Fertility Clinic, Skive Regional Hospital, Skive, Department of Clinical Medicine, Aarhus University, Skive, Denmark.
Background: In a global effort to assess expert perspectives on the use of recombinant gonadotropins, recombinant human luteinizing hormone (r-hLH) and recombinant human follicle-stimulating hormone (r-hFSH), a consensus meeting was held in Dubai. The key aim was to address three critical questions: What are the factors that influence follicle response to gonadotropins? Which categories of patients are most likely to benefit from LH supplementation? And what are the optimal management strategies for these patients?
Methods: A panel of thirty-six experts reviewed and refined the initial statements and references proposed by the Scientific Coordinator. Consensus was defined as agreement or disagreement by more than two-thirds (66%) of the panel members for each statement.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!